Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review

BACKGROUND: Dolutegravir (DTG) is a once-daily unboosted second-generation integrase-inhibitor that along with two nucleoside reverse transcriptase inhibitors is one of several regimens recommended by the United States, United Kingdom and European Union for first-line antiretroviral treatment of peo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutherford, George W., Horvath, Hacsi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063380/
https://www.ncbi.nlm.nih.gov/pubmed/27736859
http://dx.doi.org/10.1371/journal.pone.0162775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063380/
https://www.ncbi.nlm.nih.gov/pubmed/27736859
http://dx.doi.org/10.1371/journal.pone.0162775

Ejemplares similares